12
Treatment
Table 12. Treatment Goals for Non-HDL-C, LDL-C, and
Apo B
Risk Category Treatment Goal (mg/dL)
Non-HDL-C LDL-C Apo B
a
Low <130 <100 <90
Moderate <130 <100 <90
High <130 <100 <90
Very High <100 <70 <80
a
Apo B is a secondary, optional target of treatment.
Table 13. Intensity of Statin Therapy
a
High Intensity
Daily Dosage LDL-C ≥50%
Moderate Intensity
Daily Dosage LDL-C 30% to <50%
Atorvastatin 40-80 mg Atorvastatin 10-20 mg
Rosuvastatin 20-40 mg Fluvastatin 40 mg bid
Fluvastatin XL 80 mg
Lovastatin 40 mg
Pitavastatin 2-4 mg
Pravastatin 40-80 mg
Rosuvastatin 5-10 mg
Simvastatin 20-40 mg
a
Individual responses to statin therapy should be expected to vary in clinical practice. Moderate or
high intensity statin therapy is preferred unless not tolerated.
Table 15A. Single-Agents — Effects on Lipid Metabolism
Drug Class, Agents,
and Daily Doses Lipid/Lipoprotein Effects
HMG CoA reductase inhibitors
▶ Atorvastatin (10-80 mg) Lipitor
®
▶ Fluvastatin (20-80 mg) Lescol
®
▶ Lovastatin (20-80 mg)
Mevacor
®
, generics
▶ Pitavastatin (1-4 mg) Livalo
®
▶ Pravastatin (20-40 mg)
Pravachol
®
, generics
▶ Rosuvastatin (5-40 mg ) Crestor
®
▶ Simvastatin (10-40 mg)
Zocor
®
, generics
LDL-C 18%-55%
HDL-C 5%-15%
TG 7%-30%
Bile acid sequestrants
▶ Cholestyramine (4-16 g)
Questran
®
, generics
▶ Colestipol (5-20 g)
Colestid
®
, generics
▶ Colesevelam (2.6-3.8 g)
Welchol
®
LDL-C 15%-30%
HDL-C 3%-5%
TG no change or increase
